PHK
ACRS icon

Point72 Hong Kong’s Aclaris Therapeutics ACRS Stock Holding History

Point72 Hong Kong’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,784
Closed -$26K – 1772
2021
Q4 		$26K Buy
+1,784
New +$27K ﹤0.01% 1496
2021
Q3 		– Sell
-2,378
Closed -$42K – 1919
2021
Q2 		$42K Buy
+2,378
New +$54K ﹤0.01% 1507
2019
Q4 		– Sell
-6,157
Closed -$7K – 1122
2019
Q3 		$7K Buy
6,157
+408
+7% +$579 ﹤0.01% 781
2019
Q2 		$13K Buy
+5,749
New +$31.3K ﹤0.01% 831
2018
Q2 		– Sell
-424
Closed -$7K – 871
2018
Q1 		$7K Buy
424
+402
+1,827% +$8.52K ﹤0.01% 719
2017
Q4 		$1K Sell
22
-26
-54% -$633 ﹤0.01% 730
2017
Q3 		$1K Buy
48
+11
+30% +$295 ﹤0.01% 686
2017
Q2 		$1K Buy
+37
New +$1.01K ﹤0.01% 699

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Point72 Hong Kong's ACRS Position: Q1 2022 in Review

Point72 Hong Kong sold out of Aclaris Therapeutics (ACRS) in Q1 2022, closing a stake of 1,784 shares — an estimated $26K sold.

Point72 Hong Kong first reported a position in ACRS in Q2 2017 and held it in 8 quarters. The position peaked at $42K in Q2 2021. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.

  • Point72 Hong Kong reported no remaining Aclaris Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 1,784 Aclaris Therapeutics shares in Q1 2022, an estimated $26K.
  • Point72 Hong Kong first reported a position in Aclaris Therapeutics in Q2 2017 and held it in 8 quarters.
  • Point72 Hong Kong's Aclaris Therapeutics position peaked at $42K in Q2 2021.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.

Based on Point72 Hong Kong's 13F filing for Q1 2022, filed 16 May 2022.